Interaction of the chemopreventive agent resveratrol and its metabolite, piceatannol, with model membranes

Biochimica et Biophysica Acta - Biomembranes

Volumn 1788, Issue 9, 2009, Pages 1851-1860

  Wesołowska, Olga ^a   Kuzdzał, Michał ^a   Štrancar, Janez ^b   Michalak, Krystyna ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Electron spin resonance; Fluorescence spectroscopy; Microcalorimetry; Phospholipid bilayer; Piceatannol; Resveratrol

Indexed keywords

DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DRUG METABOLITE; LAURDAN; LIPID; NITROXIDE; PICEATANNOL; RESVERATROL; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL MEMBRANE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SCREENING; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; FLUORESCENCE POLARIZATION; FLUORESCENCE SPECTROSCOPY; LIPID BILAYER; LIQUID CRYSTAL; MELTING POINT; MOLECULAR PROBE; PHASE TRANSITION; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

CALORIMETRY, DIFFERENTIAL SCANNING; ELECTRON SPIN RESONANCE SPECTROSCOPY; LIPOSOMES; MEMBRANES, ARTIFICIAL; SPECTROMETRY, FLUORESCENCE; STILBENES; THERMODYNAMICS;

EID: 68749120811     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2009.06.005     Document Type: Article

References (34)

1. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 17 (2003) 1975-1985
2. Signorelli P., and Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J. Nutr. Biochem. 16 (2005) 449-466
3. Potter G.A., Patterson L.H., Wanogho E., Perry P.J., Butler P.C., Ijaz T., Ruparelia K.C., Lamb J.H., Farmer P.B., Stanley L.A., and Burke M.D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer 86 (2002) 774-778
4. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Dis. 5 (2006) 493-506
5. Pervaiz S. Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol. Drug Resist. Updat. 7 (2004) 333-344
6. Pirola L., and Frojdo S. Resveratrol: one molecule, many targets. IUBMB Life 60 (2008) 323-332
7. Roupe K.A., Remsberg C.M., Yanez J.A., and Davies N.M. Pharmacometrics of stilbenes: seguing towards the clinic. Curr. Clin. Pharmacol. 1 (2006) 81-101
8. Wieder T., Prokop A., Bagci B., Essmann F., Bernicke D., Schulze-Osthoff K., Dorken B., Schmalz H.G., Daniel P.T., and Henze G. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 15 (2001) 1735-1742
9. Wolter F., Clausnitzer A., Akoglu B., and Stein J. Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J. Nutr. 132 (2002) 298-302
10. Zheng J., and Ramirez V.D. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem. Biophys. Res. Commun. 261 (1999) 499-503
11. Teisseyre A., and Michalak K. Inhibition of the activity of human lymphocyte Kv1.3 potassium channels by resveratrol. J. Membr. Biol. 214 (2006) 123-129
12. Nabekura T., Kamiyama S., and Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun. 327 (2005) 866-870
13. Ferreira M.J.U., Duarte N., Gyemant N., Radics R., Cherepnev G., Varga A., and Molnar J. Interaction between doxorubicin and the resistance modifier stilbene on multidug resistant mouse lymphoma and human breast cancer cells. Anticancer Res. 26 (2006) 3541-3546
14. Wu C.P., Calcagno A.M., Hladky S.B., Ambudkar S.V., and Barrand M.A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 272 (2005) 4725-4740
15. Wesolowska O., Wisniewski J., Duarte N., Ferreira M.J.U., and Michalak K. Inhibition of MRP1 transport activity by phenolic and terpenic compounds isolated from Euphorbia species. Anticancer Res. 27 (2007) 4127-4134
16. Cooray H.C., Janvilisri T., van Veen H.W., Hladky S.B., and Barrand M.A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun. 317 (2004) 269-275
17. Fabris S., Momo F., Ravagnan G., and Stevanato R. Antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles and monolamellar liposomes. Biophys. Chem. 135 (2008) 76-83
18. Rhayem Y., Therond P., Camont L., Couturier M., Beaudeux J.L., Legrand A., Jore D., Gardes-Albert M., and Bonnefont-Rousselot D. Chain-breaking activity of resveratrol and piceatannol in a linoleate micellar model. Chem. Phys. Lipids 155 (2008) 48-56
19. Garcia-Garcia J., Micol V., de Gados A., and Gomez-Fernandez J.C. The cancer chemopreventive agent resveratrol is incorporated into model membranes and inhibits protein kinase C activity. Arch. Biochem. Biophys. 372 (1999) 382-388
20. Sarpietro M.G., Spatafora C., Tringali C., Micieli D., and Castelli F. Interaction of resveratrol and its trimethyl and triacetyl derivatives with biomembrane models studied by differential scanning calorimetry. J. Agric. Food Chem. 55 (2007) 3720-3728
21. Tsuchiya H., Nagayama M., Tanaka T., Furusawa M., Kashimata M., and Takeuchi H. Membrane-rigidifying effects of anti-cancer dietary factors. BioFactors 16 (2002) 45-56
22. Parasassi T., De Stasio G., d'Ubaldo A., and Gratton E. Phase fluctuation in phospholipid membranes revealed by Laurdan fluorescence. Biophys. J. 57 (1990) 1179-1186
23. Strancar J. Advanced ESR spectroscopy in membrane biophysics. In: Hemminga M.A., and Berliner L.J. (Eds). Biological Magnetic Resonance. ESR Spectroscopy in Membrane Biophysics vol. 27 (2007), Springer 49-93
24. Strancar J., Koklic T., and Arsov Z. Soft picture of lateral heterogeneity in biomembranes. J. Membr. Biol. 196 (2003) 135-146
25. Strancar J., Koklic T., Arsov Z., Filipic B., Stopar D., and Hemminga M.A. Spin label EPR-based characterization of biosystem complexity. J. Chem. Inf. Model. 45 (2005) 394-406
26. Pabst G., Hodzic A., Strancar J., Danner S., Rappolt M., and Laggner P. Rigidification of neutral lipid bilayers in the presence of salts. Biophys J. 93 (2007) 2688-2696
27. Arsov Z., and Strancar J. Determination of partition coefficient of spin probe between different lipid membrane phases. J. Chem. Inf. Model. 45 (2005) 1662-1671
28. Strancar J., and Arsov Z. Application of spin labeling EPR and ATR-FTIR spectroscopies to the study of membrane heterogeneity. In: Leitmannova A. (Ed). Advances in Planar Lipid Bilayers and Liposomes vol. 6 (2008), Elsevier, Amsterdam 139-163
29. Ghose A.K., Pritchett A., and Crippen G.M. Atomic physicochemical parameters for three dimensional structure activity relationships III: modelling hydrophobic interactions. J. Comput. Chem. 9 (1988) 80-90
30. Hendrich A.B., Wesolowska O., and Michalak K. Trifluoperazine induces domain formation in zwitterionic phosphatidylcholine but not in charged phosphatidylglycerol bilayers. Biochim. Biophys. Acta 1510 (2001) 414-425
31. Parasassi T., Krasnowska E.K., Bagatolli L., and Gratton E. Laurdan and Prodan as polarity-sensitive fluorescent membrane probes. J. Fluorescence 8 (1998) 365-373
32. Jain M.K., and Wu N.M. Effect of small molecules on the dipalmitoyl lecithin liposomal bilayer: III. Phase transition in lipid bilayer. J. Membr. Biol. 34 (1977) 157-201
33. Scheidt H.A., Pampel A., Nissler L., Gebhardt R., and Huster D. Investigation of the membrane localization and distribution of flavonoids by high-resolution magic angle spinning NMR spectroscopy. Biochim. Biophys. Acta 1663 (2004) 97-107
34. Gescher A.J., and Steward W.P. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 953-957